Residency · Residency · Nephrology

Metabolic Alkalosis

Introduction

Metabolic alkalosis is defined by a primary increase in serum bicarbonate concentration above 28 mEq/L, accompanied by a compensatory hypoventilation that raises the PaCO2 by approximately 0.7 mmHg for each 1 mEq/L rise in bicarbonate. It is the most common acid-base disorder encountered in hospitalized patients, accounting for approximately 50 percent of all acid-base disturbances. Understanding metabolic alkalosis requires recognition that two distinct processes must coexist: a generating event, which produces the initial bicarbonate gain or hydrogen ion loss, and a maintenance factor, which impairs the kidney's ability to excrete the excess bicarbonate. This distinction is critical because the kidney possesses an enormous capacity to excrete bicarbonate under normal conditions, and metabolic alkalosis persists only when one or more maintenance factors prevent renal bicarbonate elimination.

Generation of Metabolic Alkalosis

Loss of H+ (Acid)

Gastrointestinal losses represent one of the most common generating mechanisms for metabolic alkalosis. Vomiting and nasogastric suction result in the direct loss of hydrochloric acid from gastric secretions, and for each milliequivalent of hydrogen ion lost from the stomach, one milliequivalent of bicarbonate is generated and retained in the blood. This occurs because parietal cell acid secretion is accompanied by equimolar bicarbonate release into the venous blood, a process normally offset by the downstream secretion of pancreatic bicarbonate into the duodenum. When gastric acid is removed before it can stimulate pancreatic bicarbonate secretion, the net effect is a systemic bicarbonate gain.

Renal hydrogen ion losses constitute another major generating mechanism. Loop and thiazide diuretics promote metabolic alkalosis through multiple mechanisms: they induce volume contraction, which enhances proximal bicarbonate reabsorption; they increase sodium delivery to the distal nephron, which augments distal hydrogen ion and potassium secretion; and they cause chloride depletion, which impairs bicarbonate excretion. Mineralocorticoid excess, whether from primary aldosteronism, Cushing syndrome, or genetic conditions such as Liddle syndrome, generates alkalosis by stimulating ENaC-mediated sodium reabsorption in the collecting duct, which creates a lumen-negative transepithelial voltage that drives hydrogen ion and potassium secretion. The genetic tubulopathies Bartter syndrome and Gitelman syndrome mimic chronic loop diuretic and thiazide diuretic use, respectively, and produce similar alkalotic physiology.

Gain of HCO3-

Exogenous alkali administration can generate metabolic alkalosis when the bicarbonate load exceeds renal excretory capacity. This occurs with massive sodium bicarbonate infusion during resuscitation, with citrate loads from massive blood transfusion, and with citrate-based regional anticoagulation during continuous renal replacement therapy, since citrate is metabolized in the liver to bicarbonate on a 1:1 molar basis. The milk-alkali syndrome, now more accurately termed calcium-alkali syndrome, results from the combination of calcium carbonate supplementation and vitamin D, which produces hypercalcemia, metabolic alkalosis, and acute kidney injury through a self-perpetuating cycle in which hypercalcemia impairs renal bicarbonate excretion.

Contraction alkalosis occurs when bicarbonate-free fluid is lost from the extracellular space, as with loop diuretics or excessive sweating. The total body bicarbonate content remains unchanged, but its concentration in the reduced extracellular fluid volume is increased. Although contraction alkalosis is a real physiologic phenomenon, the term is somewhat misleading, as the primary maintenance mechanism is chloride depletion rather than volume contraction per se.

Post-Hypercapnic Alkalosis

Patients with chronic respiratory acidosis develop renal compensation over days through enhanced bicarbonate generation and retention. When the PaCO2 is then rapidly corrected, as occurs when a patient with COPD is intubated and mechanically ventilated, the PaCO2 normalizes but the elevated bicarbonate persists because the kidneys require hours to days to excrete the excess. This post-hypercapnic alkalosis is maintained by volume depletion and chloride depletion, which are frequently present in these patients from diuretic use and dietary restriction.

Maintenance of Metabolic Alkalosis

Volume and Chloride Depletion

Volume contraction is the most important maintenance factor for metabolic alkalosis. When effective arterial blood volume is reduced, the renin-angiotensin-aldosterone system is activated, and angiotensin II directly stimulates NHE3 in the proximal tubule, enhancing proximal sodium bicarbonate reabsorption and preventing the kidney from excreting the excess bicarbonate. Chloride depletion plays a mechanistically distinct and equally important role. Type B intercalated cells in the collecting duct secrete bicarbonate into the urine via the apical chloride-bicarbonate exchanger pendrin, and this process requires adequate luminal chloride delivery. When chloride is depleted, pendrin-mediated bicarbonate secretion is impaired, and the excess bicarbonate cannot be excreted. Additionally, decreased chloride delivery to the macula densa stimulates renin secretion, further activating the RAAS and perpetuating sodium avidity and bicarbonate retention. These overlapping mechanisms explain why metabolic alkalosis cannot resolve until both volume and chloride are repleted.

Hypokalemia

Potassium depletion is both a consequence and a perpetuator of metabolic alkalosis. When extracellular potassium is low, potassium shifts out of cells and hydrogen ions shift into cells, producing intracellular acidosis in renal tubular cells. This intracellular acidosis paradoxically stimulates hydrogen ion secretion and bicarbonate generation in the proximal tubule and collecting duct, even in the setting of systemic alkalosis. Furthermore, potassium depletion stimulates proximal tubular ammoniagenesis and activates the H-K-ATPase in the collecting duct, both of which increase net acid excretion and bicarbonate generation. The transcellular potassium-hydrogen exchange further exacerbates the alkalosis. Correction of metabolic alkalosis is impossible without concurrent correction of hypokalemia, and potassium repletion is therefore an essential component of treatment.

Mineralocorticoid Excess

Mineralocorticoid excess maintains metabolic alkalosis through a mechanism that is independent of volume status. Aldosterone drives ENaC-mediated sodium absorption in the collecting duct principal cells, generating a lumen-negative transepithelial voltage that promotes hydrogen ion secretion by type A intercalated cells and potassium secretion by principal cells. Because this mechanism operates independently of volume status, it cannot be corrected with sodium chloride infusion, and the alkalosis is therefore classified as chloride-resistant.

<image>Diagram illustrating the generation and maintenance phases of metabolic alkalosis. Show two panels: (1) Generation phase with three pathways - GI H+ loss (vomiting/NG suction), renal H+ loss (diuretics, mineralocorticoid excess), and HCO3- gain (alkali administration, contraction alkalosis). (2) Maintenance phase showing three mechanisms preventing renal HCO3- excretion: volume/chloride depletion (enhanced proximal reabsorption via NHE3 and reduced distal Cl-/HCO3- exchange via pendrin), hypokalemia (intracellular acidosis driving H+ secretion), and mineralocorticoid excess (ENaC activation driving distal H+ and K+ secretion). Connect the generation events to their respective maintenance mechanisms with arrows.</image>

Classification: Chloride-Responsive vs Chloride-Resistant

Chloride-Responsive (Urine Cl- <20 mEq/L)

Chloride-responsive metabolic alkalosis is characterized by a urine chloride concentration below 20 mEq/L, reflecting avid renal chloride retention in the setting of volume and chloride depletion. The most common causes include vomiting or nasogastric suction, remote or discontinued diuretic use, the post-hypercapnic state, and rare entities such as villous adenoma producing chloride-rich and potassium-rich diarrhea, and congenital chloride diarrhea. Treatment consists of volume repletion with 0.9 percent sodium chloride, which provides the chloride necessary for renal bicarbonate excretion, along with potassium chloride replacement to correct the invariably coexisting hypokalemia.

An important clinical nuance is that urine sodium may be misleading in the evaluation of metabolic alkalosis due to vomiting. When the serum bicarbonate exceeds the renal threshold for bicarbonate reabsorption, bicarbonaturia occurs, and the negatively charged bicarbonate obligates cation excretion, producing elevated urine sodium and potassium concentrations despite true volume depletion. In this setting, urine chloride is the more reliable marker of volume status because chloride is avidly retained by the volume-depleted kidney. This phenomenon of paradoxical natriuresis in the face of volume depletion is a common source of diagnostic confusion.

Chloride-Resistant (Urine Cl- >20 mEq/L)

Chloride-resistant metabolic alkalosis is defined by a urine chloride concentration exceeding 20 mEq/L, indicating that the kidney is not avid for chloride and that the maintenance mechanism is independent of volume status. This category is further subdivided based on the presence or absence of hypertension.

Among the hypertensive causes, primary aldosteronism, or Conn syndrome, is identified by an elevated aldosterone-to-renin ratio exceeding 30, with confirmation through salt loading, saline suppression, or fludrocortisone suppression testing. Cushing syndrome causes alkalosis because cortisol excess overwhelms the capacity of 11-beta-hydroxysteroid dehydrogenase type 2 to convert cortisol to cortisone in the collecting duct, allowing cortisol to activate the mineralocorticoid receptor. Renovascular hypertension produces alkalosis through RAAS activation. Liddle syndrome results from gain-of-function mutations in ENaC subunits, producing constitutive sodium reabsorption and volume-dependent hypertension. Apparent mineralocorticoid excess, whether genetic or acquired through licorice or carbenoxolone ingestion, results from deficiency of 11-beta-HSD2, allowing cortisol to act as the mineralocorticoid. Congenital adrenal hyperplasia due to 11-beta-hydroxylase or 17-alpha-hydroxylase deficiency produces mineralocorticoid excess through the accumulation of intermediate steroid precursors.

Among the normotensive causes, active diuretic use is the most common and can be identified by the timing of the urine collection relative to the last diuretic dose. Bartter syndrome produces a clinical phenotype mimicking chronic loop diuretic use, while Gitelman syndrome mimics chronic thiazide use, with the distinguishing features of hypomagnesemia and hypocalciuria in the latter. Severe potassium and magnesium depletion can sustain alkalosis independently, as can exogenous alkali administration in patients with impaired renal excretory function.

<image>Clinical diagnostic algorithm for metabolic alkalosis. Start with confirmation of metabolic alkalosis (elevated HCO3-, elevated pH). First decision node: check urine chloride. If urine Cl- <20 mEq/L (chloride-responsive), list causes (vomiting, NG suction, prior diuretics, post-hypercapnia) and treatment (NaCl and KCl repletion). If urine Cl- >20 mEq/L (chloride-resistant), second decision node: check blood pressure. If hypertensive, branch into high aldosterone/low renin (primary aldosteronism), high aldosterone/high renin (renovascular disease), and low aldosterone/low renin (Liddle, AME, Cushing). If normotensive, list active diuretics, Bartter, Gitelman, severe Mg/K depletion. Include renin and aldosterone levels at each decision branch.</image>

Clinical Consequences of Metabolic Alkalosis

Cardiovascular

Metabolic alkalosis produces clinically significant cardiovascular effects through multiple mechanisms. Alkalemia induces coronary vasoconstriction, reducing coronary blood flow and lowering the threshold for angina and cardiac arrhythmias. The alkalotic state increases myocardial sensitivity to digitalis, raising the risk of digitalis toxicity at otherwise therapeutic drug levels. Additionally, alkalosis produces a leftward shift of the oxyhemoglobin dissociation curve, increasing hemoglobin's affinity for oxygen and impairing oxygen delivery to peripheral tissues, which can be particularly deleterious in patients with underlying coronary artery disease or heart failure.

Respiratory

Compensatory hypoventilation is the expected respiratory response to metabolic alkalosis, with PaCO2 rising approximately 0.7 mmHg for each 1 mEq/L increase in bicarbonate. However, this respiratory compensation is limited by the hypoxic drive, and the PaCO2 rarely exceeds 55 to 60 mmHg regardless of the severity of the alkalosis. In mechanically ventilated patients, metabolic alkalosis can significantly impair liberation from the ventilator by reducing the central respiratory drive and making it difficult for the patient to generate spontaneous breaths at an adequate rate.

Neurologic

Alkalemia reduces cerebral blood flow through direct cerebrovascular vasoconstriction, producing symptoms ranging from confusion to seizures in severe cases where the pH exceeds 7.55. An important indirect neurologic consequence is the reduction in ionized calcium that accompanies alkalosis, as the increased binding of calcium to albumin at alkaline pH reduces the biologically active fraction of total serum calcium, potentially causing tetany, paresthesias, and neuromuscular irritability.

Metabolic

The metabolic consequences of alkalosis extend beyond the acid-base disturbance itself. Hypokalemia results from both transcellular potassium shifts into cells in exchange for hydrogen ions and from ongoing renal potassium wasting. Ionized hypocalcemia occurs through increased calcium-albumin binding. Hypophosphatemia and hypomagnesemia are common accompanying electrolyte derangements that further contribute to neuromuscular dysfunction and cardiac arrhythmia risk.

Management

Chloride-Responsive Alkalosis

Volume repletion with 0.9 percent sodium chloride is the cornerstone of treatment for chloride-responsive metabolic alkalosis. Normal saline provides the chloride necessary for the kidney to excrete the excess bicarbonate through pendrin-mediated chloride-bicarbonate exchange in type B intercalated cells. The rate of infusion is guided by the patient's volume status, with careful attention to avoiding volume overload in patients with underlying cardiac or hepatic disease.

Potassium chloride replacement is equally critical, as it addresses both the hypokalemia and the chloride deficit simultaneously. The typical requirement is 40 to 80 mEq per day or more, depending on the severity of the deficit, and the potassium source must be chloride-based rather than citrate or bicarbonate-based to provide the needed chloride anion.

In patients with continuous nasogastric suction, histamine H2 receptor blockers or proton pump inhibitors reduce ongoing hydrochloric acid losses from the stomach and help prevent further generation of alkalosis.

Acetazolamide at a dose of 250 to 500 mg intravenously or orally every 8 to 12 hours is particularly useful in volume-overloaded patients, such as those with congestive heart failure, who cannot tolerate the sodium load of isotonic saline. Acetazolamide inhibits proximal tubular carbonic anhydrase, inducing bicarbonaturia and directly lowering the serum bicarbonate concentration. The principal risk of acetazolamide is worsening hypokalemia, as the excreted bicarbonate acts as a non-reabsorbable anion in the distal nephron, driving potassium secretion.

For severe, refractory metabolic alkalosis with pH exceeding 7.55 that is unresponsive to the above measures, hydrochloric acid infusion may be necessary. A 0.1 to 0.2 normal HCl solution is administered through a central venous catheter, with the dose calculated using the formula: hydrogen ion deficit equals 0.5 multiplied by body weight in kilograms multiplied by the difference between the measured bicarbonate and the desired bicarbonate. The infusion rate should not exceed 0.2 mEq per kilogram per hour, with frequent arterial blood gas monitoring. Arginine hydrochloride and ammonium chloride are alternative acidifying agents but are rarely used in clinical practice: arginine hydrochloride is contraindicated in hepatic failure because it generates ammonia, and ammonium chloride carries hepatotoxic risk.

Chloride-Resistant Alkalosis

Treatment of chloride-resistant metabolic alkalosis is directed at the underlying cause. Primary aldosteronism is managed with surgical resection for unilateral adenoma or with mineralocorticoid receptor antagonists such as spironolactone at 25 to 100 mg per day or eplerenone at 25 to 50 mg twice daily for bilateral hyperplasia or surgical candidates who decline surgery. Liddle syndrome requires direct ENaC blockade with amiloride or triamterene rather than spironolactone, because the defect in Liddle syndrome is distal to the mineralocorticoid receptor, and mineralocorticoid receptor antagonism is therefore ineffective. Bartter and Gitelman syndromes are managed with potassium chloride supplementation, potassium-sparing diuretics, and nonsteroidal anti-inflammatory drugs such as indomethacin, which reduce prostaglandin-mediated renal potassium and chloride losses. Magnesium supplementation is particularly important in Gitelman syndrome, where hypomagnesemia is a characteristic and persistent finding.

Special Situations

In ventilator-dependent patients, metabolic alkalosis reduces the central respiratory drive and can impair ventilator weaning. Acetazolamide is the drug of choice in this setting, as it directly lowers serum bicarbonate and restores respiratory drive without requiring volume loading.

Post-hypercapnic alkalosis should ideally be prevented by avoiding overly rapid correction of PaCO2 in patients with chronic respiratory acidosis. If the PaCO2 has already been overcorrected, treatment consists of chloride replacement to allow renal bicarbonate excretion, along with careful reduction of minute ventilation to allow the PaCO2 to rise back toward the patient's chronic baseline.

In dialysis patients, metabolic alkalosis can be addressed by using a low-bicarbonate dialysate bath in the range of 25 to 30 mEq/L, or by increasing the chloride concentration in the dialysate.

<image>Treatment algorithm for severe metabolic alkalosis in the ICU. Start with assessment of volume status (euvolemic/hypovolemic vs hypervolemic). For hypovolemic patients, show isotonic saline infusion pathway with concurrent KCl replacement and monitoring targets (urine output, serum K+, HCO3-). For hypervolemic patients (CHF, cirrhosis), show acetazolamide 250-500 mg IV pathway with monitoring for hypokalemia. For refractory cases (pH >7.55 despite above), show HCl infusion via central line with dose calculation formula and infusion rate limits. Include a monitoring checklist: ABG q4-6h, BMP q6-8h, urine pH and Cl- to assess response.</image>

Key Clinical Pearls

• Urine chloride, not urine sodium, is the key test to classify metabolic alkalosis; urine Na+ is unreliable in vomiting because obligatory bicarbonaturia wastes sodium
• Metabolic alkalosis is never "just" volume depletion; always identify and correct the maintenance factor (Cl- depletion, K+ depletion, or mineralocorticoid excess)
• In the ICU, metabolic alkalosis depresses respiratory drive and can impair ventilator liberation; acetazolamide is the drug of choice in this setting
• The paradoxical aciduria of metabolic alkalosis occurs in severe volume/K+ depletion: despite systemic alkalosis, the kidney secretes H+ (via H-K-ATPase) to conserve K+ and reabsorb Na+
• Post-hypercapnic metabolic alkalosis is commonly iatrogenic: avoid rapidly lowering PaCO2 in chronic CO2 retainers during mechanical ventilation

References

1. Luke RG, Galla JH. It Is Chloride Depletion Alkalosis, Not Contraction Alkalosis. J Am Soc Nephrol. 2012;23(2):204-207.
2. Galla JH. Metabolic Alkalosis. J Am Soc Nephrol. 2000;11(2):369-375.
3. Khanna A, Kurtzman NA. Metabolic Alkalosis. J Nephrol. 2006;19(Suppl 9):S86-96.
4. Palmer BF, Alpern RJ. Metabolic Alkalosis. J Am Soc Nephrol. 1997;8(9):1462-1469.
5. Schwartz WB, Van Ypersele de Strihou C, Kassirer JP. Role of anions in metabolic alkalosis and potassium deficiency. N Engl J Med. 1968;279(12):630-639.

Read this lecture as Markdown